# US 2017/0247425 A1 · Rna viruses expressing il-12 for immunovirotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0247425 A1
- Document ID: US20170247425A1
- Status: Published application
- Kind: A1
- Application number: 15/441,545
- Filed: 2017-02-24
- Published: 2017-08-31
- Earliest claimed: 2016-02-25
- Assignees: Deutsches Krebsforschungszentrum; Ruprecht-Karls-Universitaet
- Applicants: Deutsches Krebsforschungszentrum; Ruprecht-Karls Universitaet
- Inventors: Guy UNGERECHTS; Christine ENGELAND; Ruta VEINALDE
- Web page: https://patentgrep.com/patent/US20170247425A1

## CPC

- C07K 14/5434: {IL-12}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2887: {against CD20}
- C07K 16/3007: {Carcino-embryonic Antigens}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/5256: {expressing foreign proteins}
- C07K 2317/622: Single chain antibody (scFv)
- C12N 2760/18043: viral genome or elements thereof as genetic vector
- C12N 2760/18432: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2760/18443: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding an IL-12 polypeptide, wherein said IL-12 polypeptide is an IL-12 fusion polypeptide comprising a p35 subunit of an IL-12 and a p40 subunit of an IL-12; to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.

## Claims

### Claim 1

A recombinant virus of the family Paramyxoviridae, comprising an expressible polynucleotide encoding an IL-12 polypeptide, wherein said IL-12 polypeptide is an IL-12 fusion polypeptide comprising a p35 subunit of an IL-12 and a p40 subunit of an IL-12.

### Claim 2 (depends on 1)

The recombinant virus of the family Paramyxoviridae of claim 1, wherein said p35 subunit and said p40 subunit of said IL-12 fusion polypeptide are from the same species.

### Claim 3 (depends on 1)

The recombinant virus of the family Paramyxoviridae of claim 1, wherein said IL-12 fusion polypeptide comprises the structure p35-linker-p40.

### Claim 4 (depends on 1)

The recombinant virus of the family Paramyxoviridae of claim 1, wherein said linker is -(glycine4-serine)n-, with n=1 to 10.

### Claim 5 (depends on 1)

The recombinant virus of the family Paramyxoviridae of claim 1, further comprising at least one expressible polynucleotide encoding a further activator of the immune response.

### Claim 6 (depends on 5)

The recombinant virus of the family Paramyxoviridae of claim 5, wherein said further activator of the immune response is a secreted immunoglobulin.

### Claim 7 (depends on 5)

The recombinant virus of the family Paramyxoviridae of claim 5, wherein said further activator of the immune response is an Fc domain of an antibody.

### Claim 8 (depends on 5)

The recombinant virus of the family Paramyxoviridae of claim 5, wherein said further activator of the immune response is a secreted soluble activator of the immune response.

### Claim 9 (depends on 5)

The recombinant virus of the family Paramyxoviridae of claim 5, wherein said further activator of the immune response is a secreted soluble anti-PD-L1 antibody.

### Claim 10 (depends on 1)

The recombinant virus of the family Paramyxoviridae of claim 1, wherein said recombinant virus is a recombinant Morbillivirus.

### Claim 11 (depends on 1)

The recombinant virus of the family Paramyxoviridae of claim 1, wherein said recombinant virus is derived from a measles virus strain Edmonston A or B.

### Claim 12 (depends on 1)

The recombinant virus of the family Paramyxoviridae of claim 1, wherein the at least one expressible polynucleotide encoding an IL-12 polypeptide is comprised in a polynucleotide encoding the recombinant virus of the family Paramyxoviridae.

### Claim 13 (depends on 1)

The recombinant virus of the family Paramyxoviridae of claim 1, wherein said polynucleotide encoding the recombinant virus of the family Paramyxoviridae comprises the nucleic acid sequence of any one of SEQ ID NOs:4 to 7, 14, and 15.

### Claim 14 (depends on 1)

A medicament comprising
(a) (i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-L1 antagonist;
(ii) a recombinant virus of the family Paramyxoviridae according to claim 1,
(iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii),
(iv) a host cell comprising the recombinant virus of the family Paramyxoviridae according to (i) or (ii) and/or a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (iii); or
(v) any combination of (i) to (iv); and
(b) at least one pharmacologically acceptable excipient.

### Claim 15 (depends on 1)

A method for treating cancer in a subject afflicted with cancer, comprising
a) contacting said subject with
(i) a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 and not comprising an expressible polynucleotide encoding a CTLA-4 antagonist, a PD-1 antagonist, a CD80 antagonist, a CD86 antagonist, or a PD-L1 antagonist;
(ii) a recombinant virus of the family Paramyxoviridae according of claim 1,
(iii) a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (i) and/or (ii),
(iv) a host cell comprising the recombinant virus of the family Paramyxoviridae according to (i) or (ii) and/or a polynucleotide encoding the recombinant virus of the family Paramyxoviridae of (iii); or
(v) any combination of (i) to (iv); and, thereby,
b) treating cancer in a subject afflicted with cancer.

### Claim 16 (depends on 15)

The method of claim 15, wherein said recombinant virus of the family Paramyxoviridae of (i) is a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 polypeptide and not comprising an expressible polynucleotide encoding a ligand for an immune checkpoint blockade protein.

### Claim 17 (depends on 15)

The method of claim 15, wherein said recombinant virus of the family Paramyxoviridae of (i) is a recombinant virus of the family Paramyxoviridae comprising an expressible polynucleotide encoding an IL-12 polypeptide as the only expressible polynucleotide encoding an activator of the immune response.

### Claim 18 (depends on 15)

The method of claim 15, wherein said cancer is a solid cancer, a metastasis, or a relapse thereof.

### Claim 19 (depends on 15)

The method of claim 15, wherein treating cancer is reducing tumor burden.

### Claim 20 (depends on 15)

The method of claim 15, wherein said cancer is malignant melanoma, head and neck cancer, hepatocellular carcinoma, pancreatic carcinoma, prostate cancer, renal cell carcinoma, gastric carcinoma, colorectal carcinoma, lymphomas or leukemias.

### Claim 21 (depends on 1)

The recombinant virus of the family Paramyxoviridae of claim 1, wherein said p35 subunit and said p40 subunit of said IL-12 fusion polypeptide are a mouse p35 subunit and a mouse p40 subunit or a variant thereof, or a human p35 subunit and a human p40 subunit or a variant thereof.
